Innohep

Tinzaparin sodium, the active ingredient in Innohep, is a low molecular weight heparin presented as a 4500 IU/mL injection for subcutaneous use. It is employed to prevent and treat thromboembolic conditions, including deep vein thrombosis, pulmonary embolism, and clot formation in hemodialysis circuits, particularly in surgical or high‑risk patients.

GNH USA supplies Innohep as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

Innohep (tinzaparin sodium) is used in the anticoagulation pathway to manage and prevent venous thromboembolism.

- Deep vein thrombosis (DVT): prevention of clot formation in surgical patients and treatment of acute DVT. - Pulmonary embolism (PE): treatment of acute pulmonary embolism. - Hemodialysis circuits: prevention of clot formation during hemodialysis procedures.

Tinzaparin sodium may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Injection site reactions: erythema, pain, or bruising at the administration site. - Minor bleeding: epistaxis, gum bleeding, or easy bruising. - Elevated liver enzymes: transient increase in hepatic transaminases.

Serious or Rare Side Effects: - Major hemorrhage: life‑threatening internal bleeding. - Thrombocytopenia: significant drop in platelet count, including heparin‑induced thrombocytopenia. - Allergic reactions: urticaria, angioedema, or anaphylaxis. - Spinal/epidural hematoma: bleeding in the spinal canal after neuraxial procedures.

When prescribing Innohep, clinicians should consider several precautionary measures to minimize risk. - Renal impairment: adjust use in patients with severe renal dysfunction. - Bleeding risk: avoid in individuals with active bleeding or high hemorrhagic risk. - Concomitant anticoagulants: monitor closely when combined with other anticoagulant or antiplatelet agents. - Surgery or invasive procedures: discontinue before major surgery to reduce bleeding complications. - Pregnancy and lactation: use only if benefits outweigh potential risks, as safety data are limited. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Tinzaparin sodium can interact with several medicines, affecting anticoagulant activity or bleeding risk.

Major Interactions (Avoid): - Concurrent use with other anticoagulants (e.g., warfarin, direct oral anticoagulants): markedly increased bleeding risk. - Thrombolytic agents (e.g., alteplase): synergistic anticoagulant effect leading to severe hemorrhage.

Moderate Interactions (Monitor Closely): - Antiplatelet drugs (e.g., aspirin, clopidogrel): enhanced bleeding tendency. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increased risk of gastrointestinal bleeding. - Certain antibiotics (e.g., vancomycin): may potentiate anticoagulant effect. - Herbal supplements containing ginkgo or garlic: may augment bleeding risk.